At the same time, it was shown that BRAF-mutant melanoma cells, which were sensitive to BRAF inhibitors, presented higher glycolytic, bioenergetic and phospholipid metabolic activity compared to resistant cells. The gene discussed is BRAF; the disease is melanoma.